Elixir Medical Corp., reported positive 12-month results for its Dynamx Coronary Bioadaptor System, with no target vessel revascularization (TVR) or stent thrombosis and adaptive remodeling of the artery to sustain healthy blood flow. The findings, from a multisite European trial, were presented during a late-breaking trials session at the PCR e-Course virtual meeting in Paris.

Minimally invasive structural heart implants are moving from mitral into tricuspid valve repair, as well as mitral valve replacement. Abbott Laboratories is presenting its latest data on all these fronts at the virtual PCR e-Course held by the European Association of Percutaneous Cardiovascular Interventions from June 25 to 27.

PARIS – Orixha SAS is developing new pulmonary ventilation technology for critical care scenarios. “Our total liquid ventilator could be of benefit through its ultra-fast ability to cool the vital organs of patients in cardiac arrest,” Fabrice Paublant, CEO of Orixha, told BioWorld. The aim is to improve survival rates and reduce the neurological complications of postcardiac arrest syndrome.

TORONTO – Once he’d enrolled in an entrepreneurial engineering course, third-year medical school student Gabriel Georges’ task was deceptively simple: come up with a device to meet an unmet medical need. Before long, Georges had pulled two other students with engineering and investor relations smarts into the project, developing a minimally invasive, long-term transcatheter heart pump that this month garnered financing from Canadian and U.S. investors.

Okami Medical Inc., which last year gained the U.S. FDA’s nod for the LOBO vascular occlusion system, has reported the close of a series D financing totaling $7.2 million. The round was led by U.S. Venture Partners and joined by members of Okami's board and other stakeholders.